USBio Logo

P3112-03A Parkin, Human, Control Peptide (RING-type E3 ubiquitin-protein ligase) CAS:

Specifications
References
Grade
Highly Purified
Specificity
Human peptide sequence is conserved in alternatively spliced isoforms (isoform 1, 465 aa; isoforms 2, 437 aa; and isoform 3, 316 aa
EU Commodity Code
38220090
Shipping Temp
Blue Ice
Storage Temp
-20°C

A 23 amino acid peptide sequence mapping near the C-terminus of human parkin.

Parkinson's is the second most common neurodegenerative disease after Alzheimer's. Parkinson's is characterized by movement disorders-triad of rigidity, resting tremor and bradykinesia. It has been attributed to loss of neurons that produce neurotransmitter dopamine. Recently a new gene, Parkin, has been identified by positional cloning (1) that is responsible for a rare autosomal recessive form of Parkinsonism, AR-JP (2). Human Parkin gene encodes a protein of 465aa (rat 465 aa; mouse 464 aa) with moderate similarity of ubiquitin at the N-terminus and RING-finger motif at the C-terminus. The gene has 12 exons, five of which (3-7) are deleted in AR-JP patients. Some other AR-JP patients have deletions affecting exon 4. Parkin is expressed in many tissues, including brain, heart, testis, and skeletal muscle. In the brain, parkin is expressed in various regions including substantia nigra. Parkin has recently been identified as an ubiquitin ligase (3).
Applications
ELISA: 1:10K-1:100K using 50-100ng of control peptide/well.
Source
Human synthetic peptide
Purity
Highly purified
Concentration
As reported
Form
Supplied as a liquid in PBS, pH 7.2
Specificity
Human peptide sequence is conserved in alternatively spliced isoforms (isoform 1, 465 aa; isoforms 2, 437 aa; and isoform 3, 316 aa
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
References
References:|(1) Kitada T et al (1998) Nature 392, 605-608; (2) Takahashi H et al (1994) Neurology 44, 437-441; Ishikawa A et al (1996) Neurology 47, 160-166; (3) Hattori SH et al (2000) Nature Genet. 25, 302-305. |A general protocol for antibody blocking with control/blocking peptides to demonstrate antibody specificity|
USBio References
No references available
Pricing
Order
Proceed to Checkout
Cart Summary
ProductSizeListYour PriceQtyExt Price
Subtotal:Subtotal:
Subtotal:Subtotal:
Total Coupon Savings:Total Coupon Savings:()
Your cart is currently empty.
- Coupon Code
Recently Viewed
  • Contact Us

    Visit our technical library or contact our support staff to answer your questions.

    Telephone:
    1-800-520-3011

    Library | Contact

    Distributors

    For customers outside of the United States, please use one of our many distributors.

    View Distributors

    Payment Methods

    We accept the following payment methods as well as pay-by-invoice.

    MasterCard Visa PayPal
    © 2023-2024 United States Biological - All Rights Reserved